Intelligent bio solutions inc. announces progress toward completion of clinical study plan required for fda 510(k) submission

New york, sept. 05, 2024 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its fda 510(k) submission.
INBS Ratings Summary
INBS Quant Ranking